Effects of Amlodipine/Benazepril on Albuminuria in Hypertensive Patients With Type 2 Diabetes Mellitus

• Status: Completed
• Trial end date: 2005-11-01
• Target enrollment: 0
• Participant gender: All

Summary

Type 2 diabetes mellitus is usually associated with high blood pressure, which is a risk factor for kidney disease. Aggressive blood pressure reduction is an important strategy to protect the kidney and reduce urinary protein which develops with kidney disease. This study will evaluate the effects of amlodipine/benazepril in reducing blood pressure and urinary protein in hypertensive subjects with type 2 diabetes mellitus.

• Phase: Phase 4

Details

• Lead Sponsor: Novartis
• Treatments: Amlodipine; Benazepril

Criteria

Inclusion Criteria:

• Mild to moderate hypertension

• Type 2 diabetes mellitus

• Presence of protein in the urine (albuminuria)

Exclusion Criteria:

• Kidney disease not caused by diabetes or hypertension

• Renal artery stenosis

• Myocardial infarction or stroke within the last 6 months

• Type 1 diabetes mellitus

• Pregnant or lactating females

• Cancer within the last 5 years